Published in J Clin Oncol on August 01, 1993
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | NCT00001430
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica (2011) 1.48
How I treat CNS lymphomas. Blood (2013) 1.20
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res (2012) 1.07
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res (2009) 1.00
Progress in central nervous system lymphomas. Br J Haematol (2014) 0.96
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood (2014) 0.89
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol (2012) 0.83
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol (2013) 0.82
The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am (2016) 0.77
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. Korean J Intern Med (2006) 0.77
Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. Leuk Lymphoma (2013) 0.77
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma. Cancer Chemother Pharmacol (2016) 0.75
Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J (2017) 0.75
Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn) (2015) 0.75
Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. Oncol Lett (2016) 0.75
New approaches in primary central nervous system lymphoma. Chin Clin Oncol (2015) 0.75
Front-line treatment of mantle cell lymphoma. Haematologica (2010) 0.75
A specific mode of microsatellite instability is a crucial biomarker in adult T-cell leukaemia/lymphoma patients. J Cancer Res Clin Oncol (2016) 0.75
Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. J Cancer Res Clin Oncol (1995) 0.75
T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol (2016) 0.75
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet (2000) 5.50
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol (1992) 4.04
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med (1998) 3.62
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst (1989) 3.48
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet (1985) 3.23
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (1986) 3.22
Randomized phase II clinical trials. Cancer Treat Rep (1985) 3.19
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1986) 3.19
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res (1985) 3.15
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
A population of fast radio bursts at cosmological distances. Science (2013) 3.03
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
The origin of the chemiluminescence of phagocytosing granulocytes. J Clin Invest (1976) 2.92
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A (1983) 2.73
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (2000) 2.66
Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol (2000) 2.66
Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol (1984) 2.65
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science (1988) 2.55
A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg (1987) 2.54
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med (1989) 2.46
Receptors for complement and immunoglobulin on human and animal lymphoid cells. Transplant Rev (1973) 2.43
Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis (1992) 2.42
Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum (2000) 2.41
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent "large cell lymphoma". Histological progression or composite malignancy? Am J Surg Pathol (1988) 2.31
Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol (1999) 2.28
Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet (1986) 2.27
Epidemiology of human T-cell leukemia/lymphoma virus. J Infect Dis (1983) 2.26
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J (1995) 2.26
Frequent presence of the Epstein-Barr virus in inflammatory pseudotumor. Hum Pathol (1995) 2.22
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol (2009) 2.20
Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. Am J Pathol (1985) 2.17
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients. J Postgrad Med (2014) 2.16
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood (2001) 2.15
A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest (1992) 2.13
Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood (1996) 2.12
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
STUDIES ON PATHOGENIC B. COLI FROM BOVINE SOURCES : II. MUTATIONS AND THEIR IMMUNOLOGICAL SIGNIFICANCE. J Exp Med (1927) 2.12
Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the kidney. Arch Pathol Lab Med (1993) 2.12
Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood (1997) 2.10
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Transdermally administered fentanyl for pain management. Clin Pharm (1992) 2.09
Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood (2000) 2.09
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol (1995) 2.02
Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med (1997) 2.01
"Fast tracking" patients with a proximal femoral fracture. J Accid Emerg Med (1996) 1.99
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol (1996) 1.99
Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol (1990) 1.99
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet (1998) 1.96
T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol (1991) 1.95
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
Mantle-cell lymphoma. Semin Hematol (1999) 1.91
Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med (1988) 1.90
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol (1986) 1.89
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol (1992) 1.84
Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg (1988) 1.81
gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol (2000) 1.80
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med (1986) 1.79